Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P33316

UPID:
DUT_HUMAN

ALTERNATIVE NAMES:
dUTP pyrophosphatase

ALTERNATIVE UPACC:
P33316; A8K650; B4DPR5; O14785; Q16708; Q16860; Q6FHN1; Q6NSA3; Q96Q81

BACKGROUND:
The mitochondrial enzyme Deoxyuridine 5'-triphosphate nucleotidohydrolase, known for its alternative name dUTP pyrophosphatase, is pivotal in DNA repair mechanisms. It efficiently prevents the misincorporation of uracil into DNA while simultaneously providing the substrate for thymidylate biosynthesis, crucial for DNA replication and cell division. Its regulatory role extends to inhibiting PPAR activity, underscoring its multifunctionality in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in Bone marrow failure and diabetes mellitus syndrome, Deoxyuridine 5'-triphosphate nucleotidohydrolase represents a significant target for drug discovery. The enzyme's dysfunction due to genetic variants underlines its potential as a therapeutic target, offering hope for innovative treatments for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.